The Native Antigen Company, one of the world’s leading suppliers of infectious disease antigens and antibodies, has signed a pre-let for a new purpose-built R&D and manufacturing facility at the Oxford Technology Park. It follows the acquisition of The Native Antigen Company in July 2020 by LGC.
This new 49,000 sq ft two-storey building, which will be ready by the summer 2021, will accommodate a mixture of bespoke laboratory, office and logistics operations.
The Native Antigen Company’s building will be constructed alongside the landmark three storey 30,000 sq ft lab-enabled office building fronting Langford Lane and the London Oxford Airport, offering suites from 4,000 sq ft for occupation summer 2021. These new buildings will join the Premier Inn hotel and Beefeater restaurant (opened in January 2020) and will be quickly followed by the next phase of flexible hi-tech buildings suitable for lab, R&D and light manufacturing.
Nick Roesen, COO of the Native Antigen Company, said: “The site presents a perfect opportunity to expand our operations. The location is right for us and was made very attractive with the ability to design the interior space to suit our business requirements. We are also excited about being part of a new science community at the Oxford Technology Park."
Angus Bates, Director at Hill Street Holdings, owners of the Oxford Technology Park, added: “We are thrilled to be working with The Native Antigen Company and will enjoy growing the community around them.
"Oxford is such an amazing place and we have been overwhelmed by the scale of demand for what we are building. Our approach is to build flexible spaces with the power, data and construction technology to cater for any form of requirement from science and technology companies. We have great plans for the next phases including smaller ‘grow on’ units as well as more large buildings.”
